- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
- First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
- FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
- FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
- Flag Stockholders: Reminder to Vote for Proposed Business Combination
- First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
More ▼
Key statistics
On Thursday, Calidi Biotherapeutics Inc (CLDI:ASQ) closed at 0.239, 66.55% above the 52 week low of 0.1435 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.229 |
---|---|
High | 0.239 |
Low | 0.2148 |
Bid | 0.221 |
Offer | 0.2289 |
Previous close | 0.2267 |
Average volume | 2.47m |
---|---|
Shares outstanding | 35.73m |
Free float | 16.09m |
P/E (TTM) | -- |
Market cap | 8.10m USD |
EPS (TTM) | -0.6154 USD |
Data delayed at least 15 minutes, as of May 09 2024.
More ▼